Roche Bets On New Cancer Drugs To Offset Patent Expiries
Roche said on Thursday strong sales of new medicines like cancer immunotherapy drug Tecentriq would help to sustain the company's growth as patents on older drugs start to expire.
Chief Executive Severin Schwan is betting he can stay ahead of the sales erosion with new medicines that include five launched in 2016 alone.
"That is an unprecedented number of launches of new medicines in a short period of time," Schwan said on a conference call after Roche reported third-quarter sales figures. "Our product pipeline is developing very well."
Chief Executive Severin Schwan is betting he can stay ahead of the sales erosion with new medicines that include five launched in 2016 alone.
"That is an unprecedented number of launches of new medicines in a short period of time," Schwan said on a conference call after Roche reported third-quarter sales figures. "Our product pipeline is developing very well."